Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Upcoming patient data
View:
Post by 99942Apophis on Feb 18, 2022 5:04pm

Upcoming patient data

Our expectations of patient data in this upcoming Newsletter should contain results of patients 25 through to and include patient 30 for the period of 90 days.

Also we should receive data on patients 21, 22, 23 and 24  for their 180 period. This will give us a sense of future patients and their success going forward of which in my opinion will score very high.
Much talk lately whether we will hear any hint of other topics of interest as in partnership/partnerships, new patients,  Ph1 of GBM & NSCLC and any advancement in the therapeutic/vaccine story! With recent changes in personal at the company my opinion is we will have better communication in both positive and negative information. Have a good long weekend.
Comment by Oilminerdeluxe on Feb 19, 2022 6:53am
83 M market cap. I will never understand markets. It's getting really close to the next update. Should be a lot of data in it. Maybe we should change name to Theralase Crypto instead.
Comment by StevenBirch on Feb 19, 2022 9:20am
I respectfully disagree Oil, we don't want to be some kind of fad that is vulnerable to big swings because those situations very seldom benefit investors like us. When the numbers come in and assuming they are as we expect they will speak for themselves and we will be rewarded.
Comment by Oilminerdeluxe on Feb 19, 2022 9:57am
Oh , I was just venting som frustrations, StevenBirch :-) I hope Vera gives a few notes next time we here anything. 
Comment by StevenBirch on Feb 19, 2022 10:53am
Yes I know, me too but I think that's what the manipulators want! Most of us here don't act on that thank god because we are now looking at 5 days +/- before what could be the real launch of TLT. Let's see what Vera has for us beyond NMIBC.
Comment by Oilminerdeluxe on Feb 19, 2022 11:05am
Fingers crossed. It would feel wonderful to climb closer to $1. Or at least past 50 cents. I don't know what it will take for the share price to take off if data so far has not done it. Perhaps we will simply have to wait for that BTD or perhaps some kind of beneficial j/v out of the blue. But solid data will of course make the wait a bit easier. Not long to go now.
Comment by winr88 on Feb 19, 2022 12:57pm
I definitely agree that very positive results for the 180 day and 90 day trials will be reported. I have mixed feelings however how much the share price will increase despite kick A$$ CR results.  I wonder how many in the market are thinking “too good to be true” and are waiting for the other shoe to drop regarding negative health effects or a big correction in trial results to the downside ...more  
Comment by CancerSlayer on Feb 19, 2022 3:14pm
  Although I consider myself an educated & objective man, a little superstitious sentiment creeps in from time to time.  I'd hate to see comments re: predictions made by a negative market jinx our results...we can leave that to the sports announcers ; ).  I actually think very few are thinking this tech is "too good to be true".  On the contrary, many think ...more  
Comment by Eoganacht on Feb 19, 2022 3:46pm
So to outdo these results Theralase must maintain a greater than 39% CR rate after 18 months. (55% of 71%) Given the results so far that sounds very likely.
Comment by DJDawg on Feb 19, 2022 7:31pm
Another interesting thing about the above graph of durable response (bcg+n-803) is that they hit 55% at 18 months but to my eyes it drops off another few steps so by 27 months it is around 25%. For these kind of graphs you get used to them leveling off as everyone who is in true remission stays that way. To have it keep dropping off makes me think that the CR isn't really a CR in a cure sense. ...more  
Comment by StevenBirch on Feb 19, 2022 4:29pm
Great post CS. I have been against some of the competition talk because to me it comes with a negative bias and not because I don't think it exists or it will hurt TLT. You are right we need every available option to treat cancer, mutiple cancers, and  with TLT being in the ballgame there is more than enough to go around to make us happy. I also don't think the market is waiting for ...more  
Comment by greaterfoolFred on Feb 19, 2022 6:42pm
I have a question, but am too lazy to find out for myself, and I am sure that most of you already know the answer.  Who are the patients being treated in the "N-803 + BCG for CIS disease" trial.  Have these people already failed BCG treatment (like in our 1433 trial?) Or is this their first treament using BCG?  Thanks, and good luck all.
Comment by CancerSlayer on Feb 20, 2022 12:18am
  Enrolled patients are BCG-unresponsive.... ClinicalTrials.gov Identifier: NCT03022825
Comment by enriquesuave on Feb 19, 2022 7:51pm
From what I understand from N-803 plus BCG results is they have 62% of CR patients maintaining CR at 12 months post 1st CR that comes out to 44% CR  of all CIS patients (62% of the 71%) at 18 months it's 55% of 71% or 39%  and 52% of 71% or 37% 24 months post 1st CR.  They make it look better than it really is.  But yes it's still very good, but hopefully we can match ...more  
Comment by DJDawg on Feb 19, 2022 8:07pm
Hey Enrique. Do you find interesting  the way the graph has several significant steps down right after the 24 m time point?
Comment by Eoganacht on Feb 19, 2022 8:09pm
I think that's the correct interpretation. It's rather deceptive the way they express it. Merck did the same thing when they published the Keytruda results. They don't give the percentage CR of the entire trial population at different times - just the percentage of the original 72% CR who remained CR at 12 months and 18 months.
Comment by CancerSlayer on Feb 20, 2022 1:26am
Enrique wrote... "From what I understand from N-803 plus BCG results is they have 62% of CR patients maintaining CR at 12 months post 1st CR that comes out to 44% CR  of all CIS patients (62% of the 71%) at 18 months it's 55% of 71% or 39%  and 52% of 71% or 37% 24 months post 1st CR.  They make it look better than it really is.  But yes it's still very good ...more  
Comment by langosta on Feb 20, 2022 7:35am
I can understand opting out, especially considering the age factor of a patient. From personal experience I was diagnosed with an oral cancer at age 83.  I understand this was  a completely different  experience, but my first reaction was, "what the heck, I'm 83 and have had a pretty good life just let it run its course I don't want an operation which may or may not be ...more  
Comment by CancerSlayer on Feb 20, 2022 9:43am
  Thanks for sharing your personal story langosta...glad you opted in & your story (as does gooseybear's) brings to light the importance of having treatment options when dealing with cancer.  Cancer treatment rarely is a one-size-fits-all model, & TLT's unique patient-friendly approach should hopefully make one's treatment decision (doc & patient) a lot easier.  ...more  
Comment by CancerSlayer on Feb 20, 2022 9:16am
  NOTE: Although N-803 is not a checkpoint inhibitor, but rather a form of interleukin or cytokine that stimulates an immune response, the drop-off in CR% after 24 months (using N-803 + BCG) suggests a similar process of T cell/immune response exhaustion may be occurring as can happen with checkpoint inhibitors.  The immune response simply can no longer be boosted, which may reflect ...more  
Comment by enriquesuave on Feb 20, 2022 9:33am
It may also be that they don't have much data beyond the 24 months mark?  
Comment by CancerSlayer on Feb 20, 2022 9:46am
Yep...could be a small sample size at that point.  But my guess is it is more than that...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250